Japan’s Takeda Pharmaceuticals has reached a deal worth up to $2.2bn to develop an Alzheimer’s vaccine made by Swiss start-up AC Immune, as drug companies race to invest in potentially lucrative new treatments for the disease.
日本武田製藥(Takeda Pharmaceutical)達成一項價值高達22億美元的協議，開發由瑞士新創公司AC Immune研發的一款阿茲海默症(Alzheimer’s)疫苗。目前各製藥公司競相投資於針對這種病症的潛在利潤豐厚的新療法。
您已閱讀9%（347字），剩餘91%（3569字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。